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Background: Hyperactivation of the renin–angiotensin system contributes to hypertension-induced upregu-
lation of vascular matrix metalloproteinases (MMPs) and remodeling, especially in the two kidney, one
clip (2K1C) hypertension model. We hypothesized that the AT1R antagonist losartan or the renin inhibitor
aliskiren, given at doses allowing similar antihypertensive effects, could prevent in vivo vascular MMPs upre-
gulation and remodeling, and collagen/elastin deposition found in 2K1C hypertension by preventing the ac-
tivation of extracellular signal-regulated kinase 1/2 (ERK 1/2) and transforming growth factor-β1 (TGF-β1).
We also hypothesized that aliskiren could enhance the effects of losartan.
Methods: 2K1C rats were treated with aliskiren (50 mg.kg−1.day−1), or losartan (10 mg.kg−1.day−1), or
both by gavage during 4 weeks.
Results: Aliskiren, losartan, or both drugs exerted similar antihypertensive effects when compared with 2K-
1C rats treated with water. Aliskiren reduced plasma renin activity in both sham and 2K-1C rats. Losartan
alone or combined with aliskiren, but not aliskiren alone, abolished 2K1C-induced aortic hypertrophy and
hyperplasia, and prevented the increases in aortic collagen/elastin content, MMP-2 levels, gelatinolytic activity,
and expression of phospho-ERK 1/2 and TGF-β1. No signiﬁcant differences were found in the aortic expression of
the (pro)renin receptor.
Conclusions: These ﬁndings show that although losartan and aliskiren exerted similar antihypertensive effects,
only losartan prevented the activation of vascular proﬁbrotic mechanisms and MMP upregulation associated
with vascular remodeling in 2K1C hypertension. Our ﬁndings also suggest that aliskiren does not enhance the
protective effects exerted by losartan.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Hyperactivation of the renin–angiotensin system (RAS) contributes
to hypertension and promotes cardiovascular remodeling [1].Mounting
evidence indicates that a proteolytic imbalance involving upregulated
matrix metalloproteinases (MMPs), especially MMP-2 [2], plays a
major role in these alterations, especially in the two kidney, one clip
(2K1C) hypertension model [3,4]. Indeed, angiotensin II increases
MMP-2 expression and activity [5,6] via activation of angiotensin II
type 1 receptors (AT1R) [1,7,8] and therefore promotes cardiovascular
remodeling [2]. Moreover, increased renin and prorenin formation acti-
vates the (pro)renin receptor (PRR) [9], which is widely expressed in
renal mesangial and in vascular smooth muscle cells (VSMCs) [10,11].ology, Faculty of Medicine of
tes, 3900, 14049-900 Ribeirao
3602 0220.
ahoo.com (J.E. Tanus-Santos).
Ltd. All rights reserved.Importantly, PRR activation exerts dual molecular functions by stimu-
lating signaling pathways that are both dependent and independent
of angiotensin II (ANG II) generation [12]. The last one elicits intracellu-
lar signaling that upregulates proﬁbrotic pathways including extracel-
lular regulated kinase 1/2 (ERK 1/2) and transforming growth factor-
β1 (TGF-β1) [13,14], which contribute to hypertensive cardiovascular
remodeling.
While antihypertensive drugs interfering with the RAS exert beneﬁ-
cial effects against the cardiovascular remodeling associated with hy-
pertension [1], it is not known whether AT1R antagonists affect
proﬁbrotic pathways and vascular MMP upregulation in hypertensive
animals or humans. Moreover, although aliskiren (a direct renin inhib-
itor) decreases angiotensin II levels and improves cardiac remodeling
[15], its effects on hypertension-induced vascular MMP upregulation
and remodeling are not known. While compelling results suggest that
aliskiren enhances the protective effects of AT1R antagonists [16,17],
the effects of this drug combination on the increases in vascular
MMPs and remodeling associated with hypertension are not known.
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Fig. 1. Systolic blood pressure (mm Hg) measured by tail-cuff method (Panel A) and
plasma renin activity (Panel B) in all experimental groups at the end of six weeks of an-
tihypertensive treatment. Data are shown as mean±S.E.M (n=11–15 per group).
*Pb0.05 for the 2K1C groups versus the Shamgroups. **Pb0.05 versus the Sham+vehicle
or versus 2K-1C+vehicle. #Pb0.05 for the 2K1C group versus the other 2K1C
groups.
1200 A. Martins-Oliveira et al. / International Journal of Cardiology 167 (2013) 1199–1205In this study, we hypothesized that the AT1R antagonist losartan
or the renin inhibitor aliskiren prevents in vivo vascular MMPs upre-
gulation and remodeling, and elastin/collagen deposition found in
2K1C hypertension [4,18] by preventing the activation of proﬁbrotic
pathways involving ERK 1/2 and TGF-β1. Because increased trans-
mural pressure is sensed by integrins [19], which transform signals
into adaptive vascular remodeling, thus affecting vascular MMP activ-
ities [20], we compared the effects of losartan and aliskiren given at
doses that allowed very similar antihypertensive effects in pilot stud-
ies. Moreover, we hypothesized that aliskiren could enhance the ef-
fects of losartan, as previously suggested [16].
2. Methods
2.1. Animals and treatments
This study was approved by the Institutional Animal Care and Use Committee of
the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, and the animals
were handled according to the guiding principles published by the National Institutes
of Health. Male Wistar rats (180–200 g) were maintained on 12-h light/dark cycle at
25 °C with free access to rat chow and water.
2K1C hypertension was induced by clipping the left renal artery with a silver clip
(0.2 mm). Sham-operated rats underwent the same surgical procedure (under general
anesthesia with ketamine 100 mg/kg and xylazine 10 mg/kg i.p.), except for the place-
ment of the renal artery clip. The systolic blood pressure (SBP) was measured by tail-
cuff plethysmography weekly, and the rats were considered hypertensive when SBP
>160 mm Hg two weeks after the surgery.
Animals were randomly assigned to one of eight groups: 2K1C and Sham groups
that received tap water; 2K1C and Sham groups that received losartan (Cozaar®;
Merck Sharp & Dohme) at 10 mg/kg per day [8]; 2K1C and Sham groups that received
aliskiren at 50 mg/kg [21] (Rasilez®; Novartis) per day; and 2K1C and Sham groups
that received the combination of aliskiren 50 mg/kg+losartan 10 mg/kg per day. The
treatments were started two weeks after 2K1C hypertension was induced and main-
tained for additional four weeks. All treatments were given daily by oral gavage and
distilled water was used as vehicle.
2.2. Plasma renin activity assay
Blood samples were collected in tubes containing 5.0 mmol/L of EDTA. Blood sam-
ples were centrifuged at 2000 ×g for 30 min at 4 °C. Plasma renin activity was deter-
mined by assessing the generation of angiotensin I by reversed phase HPLC after
incubation of plasma with a synthetic tetradecapeptide substrate at 37 °C, as previous-
ly described [22].
2.3. Morphometric analysis of the vascular wall
At the end of the experiments, animals were anesthetized and killed by decapita-
tion. The thoracic aorta was harvested, cleaned of connective tissue, and immediately
ﬁxed in 4% phosphate-buffered paraformaldehyde, pH 7.4, and embedded in parafﬁn
blocks. Four micrometer thick slices were stained with hematoxylin and eosin. Media
cross-sectional area (CSA), media to lumen diameter (M/L) and the number of VSMC
were quantiﬁed as previously described [23]. Sirus red and Orceine staining were
used to assess aortic collagen and elastin contents using ImageJ Program (Rasband,
W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://
imagej.nih.gov/ij/, 1997–2011) [4].
2.4. Measurement of aortic MMP-2 levels
Aortic tissues were homogenized in buffer containing 20 mmol/L Tris–HCl,
pH 7.4, 1 mmol/L 1,10-phenanthroline, 1 mmol/L phenylmethylsulfonyl ﬂuoride
(PMSF), 1 mmol/L N-ethylmaleimide (NEM), and 10 mmol/L CaCl2. Tissue extracts
were normalized for protein concentration and gelatin zymography was performed
as previously described [24]. The forms of MMP-2 were identiﬁed as bands at 75, 72
and 64 kDa [24].
2.5. In-situ zymography and immunoﬂuorescence for MMP-2
MMPs activity was measured in the media and intima of frozen thoracic aorta
using DQ Gelatin as the ﬂuorogenic substrate (E12055, Molecular Probes, Oregon,
USA). Proteolytic activity was detected as bright green ﬂuorescence, indicating sub-
strate breakdown and MMP enzymatic activity. Aortic MMPs activity was also co-
localized with aortic MMP-2 levels by immunoﬂuorescence. After DQ gelatin, tissue
sections were incubated with MMP-2 primary mouse anti-human monoclonal anti-
body (1:1000; Chemicon) for 1 h in dark humidiﬁed chambers. Red ﬂuorescence was
visualized by adding the rhodamine conjugated as secondary antibody (1:200; Chemi-
con) for 1 h. Sections were examined with ﬂuorescent microscopy (Leica Imaging Sys-
tems Ltd., Cambridge, England) and the image was captured at X400. MMP activity and
MMP-2 levels were evaluated by using ImageJ Program.2.6. Western blotting
Aortas from 2K1C and sham ratswere homogenized on ice-cold RIPA buffer. Fortymi-
crograms of protein extracts were subject to SDS-PAGE using a 12% polyacrylamide gel.
The proteins were then transferred onto nitrocellulose membranes and blocked with
TBST (NaCl 100 mmol/L; Tris–Cl 100 mmol/L; Tween 0.1%) containing 5% bovine serum
albumin. The membranes were incubated overnight at 4 °C with anti-MMP-2 (1:1000,
Chemicon), anti-TGF-β1 (1:1000, Chemicon), anti-phosphorylated-ERK 1/2 (anti-p-ERK
1/2; 1:2000, Santa Cruz Biotechnology) or anti-prorenin receptor (anti-PRR; 1:250,
Abcam) antibodies. Anti-β-actin (1:10,000, Millipore) was used as a loading control. The
antibodies were washed in TBST and incubated with horseradish peroxidase (HRP)-
secondary goat anti-mouse antibody (1:2000, Millipore) or HRP-secondary goat anti-
rabbit antibody (1:1000, Millipore) for 1 h. Immunolabeled proteins were visualized using
chemiluminescence ECL (Millipore) and registered by ImageQuant 350 detection system
(GE Healthcare). The signal intensities were quantiﬁed using ImageJ Program (NIH —
National Institute of Health).
2.7. Statistical analysis
Results are expressed as means±S.E.M. Comparisons between groups were
assessed by two-way or one way ANOVA followed by the Bonferroni test. A probability
valueb0.05 was considered signiﬁcant.
3. Results
3.1. Effects of aliskiren and losartan on SBP levels and plasma renin
activity
We found similar baseline SBP in all experimental groups and no
effects on SBP in the Sham groups (Fig. 1). While SBP increased pro-
gressively in 2K1C rats treated with water (208±2 mm Hg), treat-
ment of 2K1C rats with aliskiren, losartan, or both drugs exerted
similar antihypertensive effects, especially after 4 weeks of treatment
(SBP=157±2 mm Hg, 158±2 mm Hg, 146±2 mm Hg, respective-
ly; Fig. 1, Pb0.05). Similar body weight gain was found in the eight
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Fig. 2. Effects of aliskiren and/or losartan on the structural modiﬁcations induced by 2K1C hypertension in the aortas from rats. Panel A shows representative photomicrographs of
aortic samples (400×) stained by hematoxylin and eosin (H&E). Panel B shows the values for vascular smooth muscle cell number per length of aorta. Panel C shows the values for
thoracic aorta medial cross-sectional area (CSA). Panel D shows the values for media to lumen ratio (M/L). Data are shown as mean±S.E.M. (n=5–6 per group). *Pb0.05 versus the
Sham groups and versus the 2K1C+LOS and the 2K1C+ALK/LOS groups.
1201A. Martins-Oliveira et al. / International Journal of Cardiology 167 (2013) 1199–1205experimental groups (P>0.05; data not shown). The plasma renin ac-
tivity was signiﬁcantly reduced in sham rats treated with aliskiren
when compared with Sham+vehicle group (Fig. 1B, Pb0.05). Treat-
ment with aliskiren signiﬁcantly attenuated plasma renin activity in
2K-1C rats when compared with 2K1C rats treated with vehicle
(Fig. 1B, Pb0.05).Sh
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1202 A. Martins-Oliveira et al. / International Journal of Cardiology 167 (2013) 1199–1205M/L ratio found in hypertensive rats (Pb0.05; Fig. 2A–D), aliskiren
alone exerted no signiﬁcant effects, even though all treatments had
similar antihypertensive effects. In parallel with these ﬁndings, we
found increased total collagen ﬁber and elastin content per cross-
sectional area in 2K1C rats compared with the sham groups
(Pb0.05; Fig. 3A–D). Treatment with losartan or aliskiren+losartan,
but not with aliskiren alone, attenuated the increases in these param-
eters (Pb0.05; Fig. 3).3.3. Assessment of aortic MMP-2 levels by zymography
Gelatin zymography was used to assess MMP-2 levels in aortic ex-
tracts because this protease has been implicated in hypertensive vas-
cular remodeling [4,18]. 2K1C hypertension increased the aortic
levels of the 75 kDa, 72 kDa, and 64 kDa MMP-2 forms (Pb0.05;
Fig. 4). While all treatments reduced 75-kDa MMP-2 levels, only
losartan or aliskiren+losartan treatments abolished hypertension-
induced increases in the 64-kDa MMP-2 form (Pb0.05; Fig. 4).3.4. Assessment of aortic gelatinolytic activity and MMP-2 levels
Hypertension signiﬁcantly increased aortic gelatinolytic activity, as
revealed by increased green ﬂuorescence in Fig. 5A. While treatment
with losartan orwith aliskiren+losartan abolished the increases in aor-
tic gelatinolytic activity found in 2K1C rats (Pb0.05; Fig. 5A–B), treat-
ment with aliskiren alone exerted no such effect (P>0.05; Fig. 5A–B).
Interestingly, aortic MMP-2 levels assessed by immunoﬂuorescence
(red ﬂuorescence in Fig. 5 A) paralleled and co-localized with aortic
gelatinolytic activity (Fig. 5A–C).3.5. Aortic expression of MMP-2, PRR, p-ERK 1/2 and TGF-β1 protein
levels
Hypertension signiﬁcantly increased the vascular expression of
MMP-2, p-ERK 1/2, and TGF-β1, as shown in Fig. 6 (all Pb0.05).
While treatment of 2K1C rats with losartan or with aliskiren+losar-
tan abolished the increases in aortic expression of MMP-2, ERK 1/2,
and TGF-β1 (all Pb0.05; Fig. 6A, C, and D, respectively), treatment
with aliskiren alone exerted no such effect (P>0.05; Fig. 6A, C, and
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Fig. 4. A representative gelatin zymogram of aortic samples (Panel A). MMP-2 bands were
sitometric analyses for these aortic MMP-2 forms are shown in panels B–D. Data are shown
other 2K1C groups. **Pb0.05 versus the Sham groups only. #Pb0.05 versus the Sham groupWe found no signiﬁcant changes in PRR expression in hyperten-
sive rats compared with the Sham group, and no signiﬁcant effects
for drug treatments (P>0.05; Fig. 6B).4. Discussion
This is the ﬁrst study to show that the antihypertensive effects of
losartan are associated with prevention against activation of vascular
proﬁbrotic mechanisms and MMP-2 upregulation found in 2K1C hy-
pertension. Another important ﬁnding is that aliskiren, given at a
dose exerting similar antihypertensive effects to those found with
losartan, was not effective in preventing proﬁbrotic mechanisms
and vascular remodeling. Moreover, aliskiren did not improve the
protective effects exerted by losartan.
Clinical studies suggested that both AT1R antagonists or aliskiren
exert comparable antihypertensive effects [17,25,26]. While losartan
and aliskiren exerted similar effects on blood pressure in the present
study, the combination of both drugs did not lower blood pressure
signiﬁcantly more than either monotherapy, and this ﬁnding appar-
ently contrasts with clinical ﬁndings [17]. However, it is reasonable
to believe that the differences between treatments with respect to
vascular remodeling, MMP-2, or other proﬁbrotic factors are not
due to differences in antihypertensive effects and therefore differ-
ences in transmural pressure, which affects vascular MMPs [20].
As expected fromprevious studies [23,24,27], 2K1Chypertension in-
duced vascular hypertrophy, increased vascular collagen and elastin
contents, and enhancedMMP-2 levels, probably as a result of increased
angiotensin II levels [6,28]. These ﬁndings were associated with in-
creased expression of proﬁbrotic factors including p-ERK 1/2 and TGF-
β1, which clearly contribute to VSMC growth and rearrangement of ex-
tracellular matrix. The increased vascular MMP-2 levels in 2K1C rats
may activate TGF-β1 and enhance TGF-β1 intracellular signaling, thus
leading to ﬁbrosis with increased deposition of collagen and elastin
[29,30]. The antigrowth effects exerted by losartan in the present
study are supported by previous results indicating similar effects on
small resistance arteries from rats treatedwith angiontensin II [8]. Con-
sistent with the notion that the AT1R enhances collagen gene expres-
sion via ERK 1/2 signaling [31], we found increased levels of p-ERK 1/
2 and collagen deposition in the aorta from 2K1C rats, and these
changes were prevented with losartan, thus strongly suggesting a
major role for the AT1R in the vascular alterations of 2K1Chypertension.75 kDa
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Fig. 5. Effects of aliskiren, losartan, or aliskiren+losartan on aortic in situ gelatinolytic activity and MMP-2 levels in the aortas from Sham and 2K1C rats. Panel A shows represen-
tative photomicrographs of in situ gelatinolytic activity (×400), MMP-2 detected by immunoﬂuorescence (M=media; L = lumen), and their co-localization (merge) in vessel sur-
face. Panel B shows the quantiﬁcation of percentage of vessel surface area covered by bright green ﬂuorescence, which reﬂects gelatinolytic activity. Panel C shows the
quantiﬁcation of percentage of vessel surface area covered by bright red ﬂuorescence, which reﬂects MMP-2 levels. Data are shown as mean±S.E.M. (n=5–6 per group).
*Pb0.05 versus the Sham groups and versus the 2K1C+LOS and the 2K1C+ALK/LOS groups.
1203A. Martins-Oliveira et al. / International Journal of Cardiology 167 (2013) 1199–1205In contrast with losartan, aliskiren monotherapy was not effective
in preventing the structural and biochemical alterations discussed
above, even though similar antihypertensive effects were found
with both drugs. In fact, the lack of signiﬁcant effects for aliskiren
on p-ERK 1/2 and on TGF-β1 levels aligns with the lack of signiﬁcant
effects on MMP-2 levels and on the other biochemical and morpho-
logical parameters studied here. Moreover, it is intriguing that aliski-
ren did not improve the protective effects exerted by losartan, thus
contrasting with previous experimental studies [16]. These ﬁndings
suggest that renin inhibition may not have signiﬁcant effects on fun-
damental mechanisms promoting hypertensive vascular remodeling,
even though antihypertensive effects are found with aliskiren.
In line with this suggestion above, previous studies have shown
that the concentrations of aliskiren necessary to block rat renin are
approximately 100 times higher than those required to block
human renin [32]. However, in the present study, aliskiren clearly
suppressed plasma renin activity in 2K-1C, thus conﬁrming previous
ﬁndings from a study using aliskiren at the same dose used here
[21]. In addition, the decreased plasma renin activity that we found
in 2K-1C, untreated rats is in agreement with previous studies show-
ing that plasma renin activity is reduced after four weeks, during the
more chronic phase of 2 K-1 C hypertension [33,34].
The lack of signiﬁcant antigrowth effects for aliskiren may be at-
tributed to a compensatory elevation in plasma renin concentration
in 2K1C hypertension [35] and augmented PRR activation. While
overexposure of the PRR to renin/prorenin could downregulate PRR[13,36,37], we found that 2K1C hypertension or the antihypertensive
treatments exerted no effects on the expression of PRR in the aorta.
Therefore, it is possible that treatment with aliskiren enhanced PRR
signaling and activated mitogen-activated protein kinases (MAPK)-
dependent pathways. This results in VSMCs proliferation [14] and
overexpression of matrix proteins and proﬁbrotic proteins including
ERK 1/2 and TGF-β1 [38–40], especially in a context of unblocked
AT1R, which contributes to MAPK activation [41]. In contrast, while
the treatment with losartan may also increase renin concentrations,
this AT1R blocker directly prevents the activation of AT1R and MAPK
signaling pathways [41], probably exerting more effective antigrowth
effects as consistently suggested by our results.
In conclusion, our ﬁndings support the idea that the antihyperten-
sive effects exerted by losartan and aliskiren are associated with con-
trasting antigrowth effects. Only losartan prevented in vivo vascular
MMP upregulation and remodeling, and the proﬁbrotic alterations
found in 2K1C hypertension. Thus, our results suggest that blockade
of AT1R promotes better protection against the vascular remodeling
of 2K1C hypertension than renin inhibition, and that aliskiren does
not improve the effects exerted by losartan.
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Fig. 6. Expression of MMP-2 (panel A), PRR (panel B), p-ERK-1/2 (panel C), and TGF-β1 (panel D) in the thoracic aorta from Sham and 2K1C rats after treatment with vehicle, alis-
kiren (ALK), losartan (LOS) or aliskiren+losartan (ALK/LOS). Densitometric intensity corresponding to each band was normalized using β-actin expression. Data are expressed as a
ratio between the expression interest protein and β-actin expression. Data are shown as mean±S.E.M. (n=3–5 per group). * Pb0.05 versus the Sham groups and versus the
2K1C+LOS and the 2K1C+ALK/LOS groups.
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